Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Keros Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 66 to 86. Continue reading View comments
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
| 53.88 | |
| 52.54 | |
| - | |
| 55.25 | |
| 52.54 | |
| 27.02-73 | |
| 2 022 M | |
| 37 522 K | |
| 271 K | |
| -1.25 | |
| 1.222 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Keros Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 66 to 86. Continue reading View comments
Keros Therapeutics, Inc. LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company fo...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: